Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) and Briacell Therap (NASDAQ:BCTX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.
Earnings & Valuation
This table compares Agios Pharmaceuticals and Briacell Therap”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agios Pharmaceuticals | $54.03 million | 37.73 | -$412.78 million | ($7.01) | -4.87 |
| Briacell Therap | N/A | N/A | -$26.31 million | ($7.92) | -0.52 |
Institutional & Insider Ownership
15.4% of Briacell Therap shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Agios Pharmaceuticals and Briacell Therap’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agios Pharmaceuticals | -418.24% | -35.67% | -33.06% |
| Briacell Therap | N/A | -153.53% | -129.26% |
Analyst Ratings
This is a summary of current recommendations and price targets for Agios Pharmaceuticals and Briacell Therap, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agios Pharmaceuticals | 1 | 4 | 5 | 0 | 2.40 |
| Briacell Therap | 1 | 0 | 0 | 0 | 1.00 |
Agios Pharmaceuticals presently has a consensus target price of $41.25, suggesting a potential upside of 20.79%. Given Agios Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Briacell Therap.
Risk and Volatility
Agios Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
Summary
Agios Pharmaceuticals beats Briacell Therap on 8 of the 13 factors compared between the two stocks.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
